MarketPulse

drug launches

2 articles
The Motley FoolThe Motley Fool··Leo Sun

Johnson & Johnson Sheds 'Boring' Tag as Dividend King Pivots Toward Growth

J&J transforms from income stock into growth engine with 50% rally in 12 months, backed by innovative medicines and medical device expansion despite 2026 patent cliff.
JNJEPS growthdrug launches
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Healthcare Sector Poised for Growth as CVS and Vertex Eye Strategic Milestones

CVS and Vertex poised for growth through 2026 via operational improvements and expanded product pipelines. Both companies expected to deliver significant shareholder value.
CVSVRTXbiotechhealthcare stocks